Sign In
Buy AGEN
$7.00
+0.0400 (+0.575%)
At Close: Aug 10, 2026
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
02:30pm, Tuesday, 25'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopha
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
08:33am, Monday, 24'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
07:38pm, Sunday, 23'rd Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, Fe
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
10:40am, Friday, 21'st Feb 2025
Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
01:00pm, Wednesday, 12'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for
Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum
09:56am, Thursday, 06'th Feb 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed t
Are Medical Stocks Lagging Agenus (AGEN) This Year?
10:41am, Wednesday, 05'th Feb 2025
Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilim
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
02:48pm, Wednesday, 22'nd Jan 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncolo
What Makes Agenus (AGEN) a New Buy Stock
01:01pm, Monday, 20'th Jan 2025
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
10:40am, Monday, 20'th Jan 2025
Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
07:30am, Wednesday, 18'th Dec 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ba
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
07:30am, Thursday, 05'th Dec 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
08:15am, Wednesday, 27'th Nov 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizin
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options
